BioMark Diagnostics - Founder and CEO, Rashid Bux
Founder and CEO, Rashid Bux
Source: BioMark Diagnostics
  • BioMark Diagnostics (BUX) and the Icahn School of Medicine at Mount Sinai in New York have signed a research agreement to collaborate on clinical studies
  • These studies relate to early lung cancer diagnosis for at-risk population using a set of proprietary plasma biomarkers and machine learning algorithms
  • The partnership also aims to develop a diagnostic test to determine lung cancer subtype and stage using CTC (exosomes) and metabolomics
  • BioMark is a Canada-based company that is developing its advanced stage cancer diagnostic business
  • BioMark Diagnostics Inc. was unchanged at C$0.295 at 11:03 ET

BioMark Diagnostics (BUX) and the Icahn School of Medicine at Mount Sinai in New York have signed a research agreement to collaborate on clinical studies.

These studies are related to early lung cancer diagnosis for at risk population using a set of proprietary plasma biomarkers and machine learning algorithms discovered and developed by BioMark.

Icahn Mount Sinai and BioMark have agreed to explore multiple areas of collaboration as they share a mutual interest in researching, developing, and commercializing an integrative “multiomics” test for early detection and management of cancer following a successful outcome of this study.

The partnership also aims to develop a diagnostic test to determine lung cancer subtype and stage using CTC (exosomes) and metabolomics.

This initiative is part of BioMark’s effort to commercialize its liquid-biopsy technology that leverages the latest advances in metabolomics and machine learning algorithms in the US.

The test developed through this dynamic collaboration would offer the opportunity to screen nearly 16 million individuals eligible for lung cancer screening under current US guidelines.

However, the current national lung cancer screening rates are still less than 6 per cent and could be significantly improved with a widely accessible blood-based cancer screening.

“This is a significant opportunity and moment for our company as we start our expansion into the US where we intend to offer lung cancer screening solution that is affordable, accessible, and robust compared to existing options,” noted Rashid Bux, CEO of BioMark

“I always emphasize the importance of early detection of lung cancer and the need for intensified research in this particular field,” stated Fred R. Hirsch, MD, PhD, FASCO, Executive Director of the multidisciplinary Centre of Thoracic Oncology and Director of the Centre of Excellence for Thoracic Oncology at The Tisch Cancer Institute at Mount Sinai.

“The use of liquid biopsy in lung cancer is a reality in advanced disease, and early detection represents a new frontier for this technology” said Christian Rolfo, MD, PhD, MBA,Dr.h.c., Associate Director of Clinical Research at the Centre of Thoracic Oncology at The Tisch Cancer Institute at Mount Sinai.

BioMark is a Canada-based company that is developing its advanced stage cancer diagnostic business.

BioMark Diagnostics Inc. was unchanged at C$0.295 at 11:03 ET.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.